Volume : 09, Issue : 07, July – 2022



Authors :

Surendra Singh, Alok Pal Jain, Amit Nayak

Abstract :

Objective: The objective of the paper is synthesis and characterization of sulfonamide-thiazole derived acetamide derivatives and evaluated for them for the anticancer potential.
Material and methods: The sulfonamide-thiazole derived acetamide derivatives has been prepared by the two step process, in first step, 2-chloro-N-(4-((2,3-dihydro-4H-1,4-oxazin-4-yl)sulfonyl)phenyl) acetamide (Compound 2) was synthesized, and in step 2, N-(4-((2,3-dihydro-4H-1,4-oxazin-4-yl)sulfonyl)phenyl)-2-((4-substitutedthiazol-2-yl)amino)acet-amide (Compound 3) was synthesized by the reaction of synthesized compound 2 with different 4-substituted thiazol-2-amine to from the final compounds (compound 3). Total eleven compounds have been synthesized and characterized by physicochemical and IR, NMR and MASS spectral analysis. The final compounds (SA-1 to SA-11) have been evaluated for anticancer activity by SRB assay method.
Result and Discussion: The IR spectrum of the compounds (SA-1 to SA-11) has shown the characteristics peak (cm-1) of N-H peak at 3331, N-H peak at 3118, aromatic C-H peak at 3039, C=O peak at 1672, C-H aliphatic peak at 2938, C-Cl peak at 850, C-Br peak at 1018, C-F peak at 1102, N-O peak at 1358 and N=O peak at 1562. The 1HNMR spectra depicted the peak of N-H at 10.25 ppm, Thiazole-H peak at 6.25 ppm, CH2 peak at 4.19. The 13CNMR spectrum denotes the peak in ppm of C=O at 170.5, C=N at 162.3 and CH2 at 45.6. Compound SA-1, mass spectrum has shown peak at m/z = 414.02, which matches the chemical formula C15H15ClN4O4S2. The result data of the synthesized compounds by SRB assay stated the IC50 value of compounds SA-1 (7.7), SA-3 (9.5), SA-4 (14.7) and SA-11 (8.1) has shown better activity as compared to the standard drug paclitaxel (31.1)
Conclusion: The Cl, Br, NO2 and F compounds enhance the activity when it attached to 4-position of the thiazole ring as well as presence of sulfonamide bearing thiazole with addition to electronegative atom enhance the anticancer activity of compounds
Keywords: Anticancer activity, thiazole, sulfonamide, SRB assay, acetamide

Cite This Article:

Please cite this article in press Surendra Singh et al, Synthesis, Characterization And Anticancer Screening Of New Sulfonamide-Thiazole Derived Acetamide Compounds., Indo Am. J. P. Sci, 2022; 09(7).,

Number of Downloads : 10


1. Berest GG, Voskoboynik OY, Kovalenko SI, Antypenko OM, Nosulenko IS, Katsev AM, Shandrovskaya OS. Synthesis and biological activity of novel N-cycloalkyl-(cycloalkyl aryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3c]quinazoline-6 yl)thio]-acetamides. Eur J Med Chem 2011; 46: 6066–6074.
2. Bhateja P, Chiu M, Wildey G. Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer. Cancer Med. 2019; 8(4): 1459-1466.
3. Chiang A, Detterbeck FC, Stewart T, Decker RH, Tanoue L. Chapter 48: Non-small cell lung cancer. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2019.
4. Hussein EM, Al-Rooqi MM, Abd El-Galil SM, Ahmed SA. Design, synthesis, and biological evaluation of novel N-4-substituted sulfonamides: acetamides derivatives as dihydrofolate reductase (DHFR) inhibitors. BMC Chem 2019; 13: 91.
5. Xiang Y, Wang XH, Yang Q, Tan JL, Jang HJ, Zuo H, Shin DS. Rational design, synthesis, and biological activity of N-(1,4-benzoxazinone) acetamide derivatives as potent platelet aggregation inhibitors. Bull Korean Chem Soc 2018; 39: 146–155.
6. De-Santana TI, Barbosa MO, Gomes PATM, da Cruz ACN, da Silva TG, Leite ACL. Synthesis, anticancer activity and mechanism of action of new thiazole derivatives. Eur J Med Chem 2018; 144: 874–886.
7. Singh RK. Molecular modeling, synthesis, antibacterial and cytotoxicity evaluation of sulfonamide derivatives of benzimidazole, indazole, benzothiazole and thiazole. Bioorg Med Chem 2018; 26: 3414–3428.
8. Hussein EM. Ammonium chloride-catalyzed four-component sonochemical synthesis of novel hexahydroquinolines bearing a sulfonamide moiety. Russ J Org Chem 2015; 51: 54–64.
9. Hussein EM, Al-Shareef HF, Aboellil AH, Elhady HA. Synthesis of some novel 60-(4-chlorophenyl)-3,40-bipyridine-30-carbonitriles: assessment of their antimicrobial and cytotoxic activity. Z Naturforsch 2015; 70b: 783–795.
10. Liu Z, Zhou Z, Tian W, Fan X, Xue D, Yu L, Yu Q, Long YQ. Discovery of novel 2-N-aryl-substituted benzenesulfonamido-acetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities. Chem Med Chem 2012; 7: 680–693.
11. Alsaid MS, Ghorab MM, Al-Dosari MS, Hamed MM. Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzene sulfonamide moiety. Eur J Med Chem 2011; 46: 201–207.
12. Ghorab MM, Ragab FA, Heiba HI, El-Hazek RM. Anticancer and radio-sensitizing evaluation of some new thiazolopyrane and thiazolopyranopyrimidine derivatives bearing a sulfonamide moiety. Eur J Med Chem 2011; 46: 5120–5126.
13. Taweel AM, Alafeefy AM, Ghorab MM, Noaman E. Discovering some novel tetrahydroquinoline derivatives bearing the biologically active sulfonamide moiety as a new class of antitumor agents. Eur J Med Chem 2010; 45: 1849–1853.
14. Alqasoumi SI, Al-Taweel AM, Alafeefy AM, Noaman E, Ghorab MM. Novel quinolines and pyrimido[4,5-b] quinolines bearing biologically active sulfonamide moiety as a new class of antitumor agents. Eur J Med Chem 2010; 45: 738–744.
15. Al-Said MS, Ghorab MM, Al-qasoumi SI, El-Hossary EM, Noaman E. Synthesis and in-vitro anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5,6,7,8 tetrahydroquinolin-1-(4H)-yl]benzenesulfonamides. Eur J Med Chem 2010; 45: 3011–3018.
16. Bouska J, Bell RL, Lesniewski R, Henkin J, Sheppard GS. Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett 2006; 16: 3574–3577.
17. Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol 2018; 52(1): 103–109.